-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gaithersburg, Maryland, October 18, 2021/PRNewswire/ - Novavax, Inc.
During the European World Vaccine Congress 2021
The meeting details are as follows:
date: |
Wednesday, October 20, 2021 |
time: |
11:30 am – 12:00 pm Central European Time (CET) / |
title: |
Novavax NanoFlu vaccine and new coronary pneumonia NanoFlu vaccine development update |
Novavax participants: |
Vivek Shinde, MD, Vice President of Clinical Development |
date: |
Wednesday, October 20, 2021 |
time: |
11:30 am – 12:00 pm Central European Time (CET) / |
title: |
Novavax NanoFlu vaccine and new coronary pneumonia NanoFlu vaccine development update |
Novavax participants: |
Vivek Shinde, MD, Vice President of Clinical Development |
date:
Wednesday, October 20, 2021
11:30 am – 12:00 pm Central European Time (CET) /
Novavax NanoFlu vaccine and new coronary pneumonia NanoFlu vaccine development update
Vivek Shinde, MD, Vice President of Clinical Development
Wednesday, October 20, 2021
date:
date:
Date:Date:Wednesday, October 20, 2021
Wednesday, October 20, 2021
Wednesday, October 20, 2021time:
11:30 am – 12:00 pm Central European Time (CET) /
time:
time:
Time:time:11:30 am – 12:00 pm Central European Time (CET) /
11:30 am – 12:00 pm Central European Time (CET) /
11:30 am – 12:00 pm Central European Time (CET) /
Novavax NanoFlu vaccine and new coronary pneumonia NanoFlu vaccine development update
title:
title:
Title:Title:Novavax NanoFlu vaccine and new coronary pneumonia NanoFlu vaccine development update
Novavax NanoFlu vaccine and new coronary pneumonia NanoFlu vaccine development update
Novavax NanoFlu vaccine and new coronary pneumonia NanoFlu vaccine development updateNovavax participants:
Vivek Shinde, MD, Vice President of Clinical Development
Novavax participants:
Novavax participants:
Novavax participants:Novavax participants:Vivek Shinde, MD, Vice President of Clinical Development
Vivek Shinde, MD, Vice President of Clinical Development
Vivek Shinde, MD, Vice President of Clinical DevelopmentFor more information or registration, please visit the conference website
Conference website
About Novavax
About Novavax